Panama vs Sudan: HIV/AIDS deaths averted by antiretroviral therapy
Panama
934.45 deaths
in 2024
Sudan
958.82 deaths
in 2024
Panama rank
76th
Sudan rank
75th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Panama
- Sudan
How they compare
Sudan currently reports 958.82 deaths against 934.45 deaths in Panama, a difference of 24.37 deaths.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Sudan ahead.
Panama ranks 76th and Sudan ranks 75th of 157 countries.
Across the 4 decades both report, Panama averaged higher in 3 and Sudan in 1.
Head to head by decade
| Decade | Panama | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 8.02 deaths | 0 deaths | 8.02 deaths | Panama |
| 2000s | 346.22 deaths | 104.25 deaths | 241.97 deaths | Panama |
| 2010s | 668.17 deaths | 556.8 deaths | 111.37 deaths | Panama |
| 2020s | 769.48 deaths | 1,050 deaths | 280.76 deaths | Sudan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Panama or Sudan?
- Sudan, at 958.82 deaths against 934.45 deaths in Panama as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Panama and Sudan?
- 24.37 deaths, with Sudan ahead.
- How many years of comparable data are there for Panama and Sudan?
- 35 years are reported by both, from 1990 to 2024.
- How do Panama and Sudan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Panama ranks 76th and Sudan ranks 75th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.